NASDAQ: ASLNAslan Pharmaceuticals Ltd Stock
$4.20+0.00 (+0%)
Updated Jun 2, 2023
ASLN Price
$4.20
Fair Value Price
$24.90
Market Cap
$67.56M
52 Week Low
$1.70
52 Week High
$4.95
P/E
-1.12x
P/B
6.83x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
5.1
Operating Cash Flow
N/A
Beta
0.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ASLN Overview
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ASLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASLN ($4.20) is undervalued by 83.13% relative to our estimate of its Fair Value price of $24.90 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ASLN ($4.20) is significantly undervalued by 83.13% relative to our estimate of its Fair Value price of $24.90 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ASLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ASLN due diligence checks available for Premium users.
Be the first to know about important ASLN news, forecast changes, insider trades & much more!
ASLN News
Valuation
ASLN fair value
Fair Value of ASLN stock based on Discounted Cash Flow (DCF)
Price
$4.20
Fair Value
$24.90
Undervalued by
83.13%
ASLN ($4.20) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ASLN ($4.20) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ASLN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ASLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.12x
Industry
11.51x
Market
52.69x
ASLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.83x
Industry
5.2x
ASLN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ASLN's financial health
Profit margin
Revenue
$0.0
Net Income
-$19.1M
Profit Margin
0%
Assets to liabilities
Assets
$60.3M
Liabilities
$50.4M
Debt to equity
5.1
ASLN's short-term assets ($60.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASLN's short-term assets ($60.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ASLN vs Biotech Stocks
Aslan Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.